CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 630 enrolled
Drug / intervention
Interferon gamma human recombinant (IFN-G)drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05054114
NCT05054114N/ACompleted
CompareCT.gov

Prospective Randomized Open-label Comparative Study of the Use of Intranasal Form of Interferon Gamma Human Recombinant in Patients for the Prevention of Acute Respiratory Viral Infections, Including COVID-19

SPP Pharmaclon Ltd.·interventional·Posted Sep 23, 2021·Updated Aug 9, 2024

In Brief

A clinical study evaluating Interferon gamma human recombinant (IFN-G) for COVID-19 Respiratory Infection and Acute Respiratory Disease. Completed, enrolled 630 participants across 1 site.

Detailed Summary

It is known that the pretreatment with exogenous interferon blocks SARS-CoV-2 infection, but intervention is much more effective if administered prior to infection. In this study the primary aim is to investigate 28-day regime of nasal interferon gama use in healthy participants for COVID-19 and other respiratory infections prevention.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19 Respiratory Infection, Acute Respiratory Disease
CountriesRussia
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedSep 23, 2021
Enrollment StartDec 21, 2020
Primary CompletionMay 25, 2021
Study CompletionSep 2, 2021
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 4.8 years ago

Interventions

Interferon gamma human recombinant (IFN-G)drug

nasal form